These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9272345)
1. Absolute efficacy of acellular pertussis vaccines in household settings. Storsaeter J; Gustafsson L Dev Biol Stand; 1997; 89():153-9. PubMed ID: 9272345 [TBL] [Abstract][Full Text] [Related]
2. Estimation of pertussis vaccine efficacy in the presence of covariates in three randomized trials. Blackwelder WC; VanRaden MJ; Deloria MA Dev Biol Stand; 1997; 89():161-6. PubMed ID: 9272346 [TBL] [Abstract][Full Text] [Related]
3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR; Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582 [TBL] [Abstract][Full Text] [Related]
4. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Heininger U; Stehr K; Christenson P; Cherry JD Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis. Schmitt HJ Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573 [No Abstract] [Full Text] [Related]
6. Implications of different study designs for the evaluation of acellular pertussis vaccines. Fine PE Dev Biol Stand; 1997; 89():123-33. PubMed ID: 9272342 [TBL] [Abstract][Full Text] [Related]
7. The Swedish efficacy trial of acellular pertussis vaccines--update and time for reflection. Olin P Dev Biol Stand; 1991; 73():33-6. PubMed ID: 1778327 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing the analysis of secondary prevention of pertussis. Wirsing von König CH; Schmitt HJ; Bogaerts H; Bock HL; Laukamp S; Kiederle S; Postels-Multani S Dev Biol Stand; 1997; 89():175-9. PubMed ID: 9272349 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness of whole-cell pertussis vaccines. Plotkin SA Dev Biol Stand; 1997; 89():171-4. PubMed ID: 9272348 [TBL] [Abstract][Full Text] [Related]
10. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Stehr K; Cherry JD Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571 [No Abstract] [Full Text] [Related]
11. Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Heijbel H; Rasmussen F; Olin P Dev Biol Stand; 1997; 89():99-100. PubMed ID: 9272337 [No Abstract] [Full Text] [Related]
12. The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Cherry JD Dev Biol Stand; 1997; 89():181-6. PubMed ID: 9272350 [TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175 [TBL] [Abstract][Full Text] [Related]
14. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328 [TBL] [Abstract][Full Text] [Related]
15. Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Granoff DM; Rappuoli R Dev Biol Stand; 1997; 89():379-89. PubMed ID: 9272376 [TBL] [Abstract][Full Text] [Related]
16. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan. Isomura S Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Gustafsson L; Hessel L; Storsaeter J; Olin P Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988 [TBL] [Abstract][Full Text] [Related]
18. [Time for booster doses against whooping cough for 10-year-old children]. Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889 [TBL] [Abstract][Full Text] [Related]
19. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants. Beloradsky BH Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574 [No Abstract] [Full Text] [Related]
20. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study. Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]